TY - JOUR
T1 - Network meta-analyses comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis at 24-28 and 48-52 weeks
AU - Egeberg, Alexander
AU - Kristensen, Lars Erik
AU - Puig, Luis
AU - Rich, Phoebe
AU - Smith, Saxon D
AU - Garrelts, Alyssa
AU - See, Kyoungah
AU - Holzkaemper, Thorsten
AU - Fotiou, Konstantinos
AU - Schuster, Christopher
PY - 2023/12
Y1 - 2023/12
N2 - BACKGROUND: Available network meta-analyses (NMAs) comparing the efficacy of biologics in nail psoriasis (NP) have not included recently approved biologics such as bimekizumab nor have they provided comparisons up to 1 year.OBJECTIVE: We conducted two NMAs that update and extend results from a previous NMA comparing biologics for achieving complete resolution of NP.METHODS: Bayesian NMAs were performed using a generalized linear model with a logit link to model the binary outcome of nail clearance at weeks 24-28 and 48-52.RESULTS: For the NMA at weeks 24-28, which included seven biologics and placebo, the absolute probability of achieving complete resolution of NP was highest for ixekizumab (46.4%; 95% credibility interval [CrI] 35.2-58.0), followed by brodalumab (37.1%; 95% CrI 17.1-62.2) and bimekizumab (30.3%; 95% CrI 12.7-53.9). For the NMA at weeks 48-52, which included six biologics, the absolute probability was highest for ixekizumab (77.2%; 95% CrI 51.1-93.4), followed by adalimumab (75.6%; 95% CrI 61.5-87.3) and brodalumab (71.9%; 95% CrI 38.4-93.2).CONCLUSION: Among biologics included in these two NMAs, ixekizumab has the highest absolute probability of achieving complete resolution of NP. Results may help to inform treatment decisions for patients with NP.
AB - BACKGROUND: Available network meta-analyses (NMAs) comparing the efficacy of biologics in nail psoriasis (NP) have not included recently approved biologics such as bimekizumab nor have they provided comparisons up to 1 year.OBJECTIVE: We conducted two NMAs that update and extend results from a previous NMA comparing biologics for achieving complete resolution of NP.METHODS: Bayesian NMAs were performed using a generalized linear model with a logit link to model the binary outcome of nail clearance at weeks 24-28 and 48-52.RESULTS: For the NMA at weeks 24-28, which included seven biologics and placebo, the absolute probability of achieving complete resolution of NP was highest for ixekizumab (46.4%; 95% credibility interval [CrI] 35.2-58.0), followed by brodalumab (37.1%; 95% CrI 17.1-62.2) and bimekizumab (30.3%; 95% CrI 12.7-53.9). For the NMA at weeks 48-52, which included six biologics, the absolute probability was highest for ixekizumab (77.2%; 95% CrI 51.1-93.4), followed by adalimumab (75.6%; 95% CrI 61.5-87.3) and brodalumab (71.9%; 95% CrI 38.4-93.2).CONCLUSION: Among biologics included in these two NMAs, ixekizumab has the highest absolute probability of achieving complete resolution of NP. Results may help to inform treatment decisions for patients with NP.
KW - Humans
KW - Network Meta-Analysis
KW - Bayes Theorem
KW - Adalimumab/therapeutic use
KW - Psoriasis/drug therapy
KW - Nail Diseases/drug therapy
KW - Severity of Illness Index
KW - Biological Products/therapeutic use
KW - Treatment Outcome
UR - http://www.scopus.com/inward/record.url?scp=85173461528&partnerID=8YFLogxK
U2 - 10.1080/09546634.2023.2263108
DO - 10.1080/09546634.2023.2263108
M3 - Journal article
C2 - 37781881
SN - 0954-6634
VL - 34
SP - 2263108
JO - The Journal of dermatological treatment
JF - The Journal of dermatological treatment
IS - 1
M1 - 2263108
ER -